Protein tyrosine phosphatase receptor‑type O expression as a prognostic marker in patients with acute coronary syndrome undergoing percutaneous coronary intervention: A prospective study

Hao,Minghui; Guo,Ming; Yan,Rui

doi:10.3892/etm.2021.9852

Protein tyrosine phosphatase receptor‑type O expression as a prognostic marker in patients with acute coronary syndrome undergoing percutaneous coronary intervention: A prospective study

Authors:
- Minghui Hao
- Ming Guo
- Rui Yan
View Affiliations

Affiliations: Department of Cardiology, Beijing Luhe Hospital, Capital Medical University of Medical Sciences, Beijing 101100, P.R. China
Published online on: February 26, 2021 https://doi.org/10.3892/etm.2021.9852
Article Number: 435
Copyright: © Hao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Optimal clinical indicators are crucial for evaluating the prognosis of patients with acute coronary syndrome (ACS). In the present study, the potential prognostic value of protein tyrosine phosphatase receptor‑type O (PTPRO) expression in the peripheral blood mononuclear cells of patients with ACS undergoing percutaneous coronary intervention (PCI) was investigated. Patients diagnosed with ACS were prospectively recruited, and PTPRO expression in mononuclear cells separated from peripheral blood was assessed by western blotting. The prognosis was judged by the occurrence of major adverse cardiovascular events. Cox regression analyses were performed to assess the association between PTPRO expression and prognosis. In the enrolled 185 patients with ACS, PTPRO expression was lower after PCI compared with that before PCI (P<0.05). Although the pre‑PCI PTPRO expression did not differ significantly between the good and poor prognosis groups, PTPRO expression after PCI was significantly lower in the good prognosis group compared with the poor prognosis group (P<0.05). The area under the receiver operating characteristic curve for the prognostic value of post‑PCI PTPRO expression was significantly greater than that for pre‑PCI PTPRO expression (P<0.05). Cox regression analysis identified high post‑PCI PTPRO expression as an independent risk factor for poor prognosis in patients with ACS (P<0.05), and further analysis indicated that the post‑PCI PTPRO expression level was associated with the prognosis of patients with ACS (P<0.05). PTPRO expression in peripheral blood mononuclear cells after PCI is associated with the prognosis of patients with ACS, with high PTPRO expression indicating a high risk of poor prognosis in patients with ACS.

View Figures

View References

1	Lin F, Yang Y, Guo Q, Xie M, Sun S, Wang X, Li D, Zhang G, Li M, Wang J and Zhao G: Analysis of the molecular mechanism of acute coronary syndrome based on circRNA-miRNA network regulation. Evid Based Complement Alternat Med. 2020(1584052)2020.PubMed/NCBI View Article : Google Scholar
2	Chandiramani R, Cao D and Mehran R: Periprocedural anticoagulation in non-ST-segment elevation acute coronary syndrome: Time to reassess? Ann Transl Med. 8(556)2020.PubMed/NCBI View Article : Google Scholar
3	Huang ZS, Zheng ZD, Zhang JW, Tang LL, Zhou LL, Li SH, Xie XJ, Dong RM, Zhu JM and Liu JL: Association of major adverse cardiovascular events and cardiac troponin-I levels following percutaneous coronary intervention: A three-year follow-up study at a single center. Eur Rev Med Pharmacol Sci. 24:3981–3992. 2020.PubMed/NCBI View Article : Google Scholar
4	Ming F and Sun Q: Epigenetically silenced PTPRO functions as a prognostic marker and tumor suppressor in human lung squamous cell carcinoma. Mol Med Rep. 16:746–754. 2017.PubMed/NCBI View Article : Google Scholar
5	Dong H, Ma L, Gan J, Lin W, Chen C, Yao Z, Du L, Zheng L, Ke C, Huang X, et al: PTPRO represses ERBB2-driven breast oncogenesis by dephosphorylation and endosomal internalization of ERBB2. Oncogene. 36:410–422. 2017.PubMed/NCBI View Article : Google Scholar
6	Yan S, Cheng M, Duan Q, Wang Z, Gao W, Ren B and Xu D: MiR-6803-5p promotes cancer cell proliferation and invasion via PTPRO/NF-κB axis in colorectal cancer. Mediators Inflamm. 2019(8128501)2019.PubMed/NCBI View Article : Google Scholar
7	Xu D, Wang X, Yan S, Yin Y, Hou J, Wang X and Sun B: Interaction of PTPRO and TLR4 signaling in hepatocellular carcinoma. Tumour Biol. 35:10267–10273. 2014.PubMed/NCBI View Article : Google Scholar
8	Qi C, Shao Y, Liu X, Wang D and Li X: The cardioprotective effects of icariin on the isoprenaline-induced takotsubo-like rat model: Involvement of reactive oxygen species and the TLR4/NF-κB signaling pathway. Int Immunopharmacol. 74(105733)2019.PubMed/NCBI View Article : Google Scholar
9	Tang YL, Jiang JH, Wang S, Liu Z, Tang XQ, Peng J, Yang YZ and Gu HF: TLR4/NF-κB signaling contributes to chronic unpredictable mild stress-induced atherosclerosis in ApoE-/- mice. PLoS One. 10(e0123685)2015.PubMed/NCBI View Article : Google Scholar
10	Zhao J, Yan S, Zhu X, Bai W, Li J and Liang C: PTPRO exaggerates inflammation in ulcerative colitis through TLR4/NF-κB pathway. J Cell Biochem. 121:1061–1071. 2020.PubMed/NCBI View Article : Google Scholar
11	Liang C, Wang X, Hu J, Lian X, Zhu T, Zhang H, Gu N and Li J: PTPRO promotes oxidized low-density lipoprotein induced oxidative stress and cell apoptosis through toll-like receptor 4/nuclear factor κB pathway. Cell Physiol Biochem. 42:495–505. 2017.PubMed/NCBI View Article : Google Scholar
12	Chinese Medical Association Emergency Physicians Branch, Chinese Medical Association Cardiovascular Medicine Branch and Chinese Medical Association Laboratory Medicine Branch. Guidelines for the rapid diagnosis and treatment of acute coronary syndrome in the emergency department. Chin J Emerg Med. 25:397–404. 2016.
13	Zhao JW, Shi G, Ping JD and Ming L: Study on the negative regulation of TIPE2 from peripheral blood mononuclear cells on tissue factor in patients with bronchial asthma. Zhonghua Yi Xue Za Zhi. 98:2889–2893. 2018.PubMed/NCBI View Article : Google Scholar : (In Chinese).
14	Ye G, Qin Y, Wang S, Pan D, Xu S, Wu C, Wang X, Wang J, Ye H and Shen H: Lamc1 promotes the Warburg effect in hepatocellular carcinoma cells by regulating PKM2 expression through AKT pathway. Cancer Biol Ther. 20:711–719. 2019.PubMed/NCBI View Article : Google Scholar
15	Gowdak LHW: Atherosclerosis, inflammation, and genetics- and you thought it was just LDL-cholesterol. Arq Bras Cardiol. 114:273–274. 2020.PubMed/NCBI View Article : Google Scholar
16	Frodermann V, Rohde D, Courties G, Severe N, Schloss MJ, Amatullah H, McAlpine CS, Cremer S, Hoyer FF, Ji F, et al: Exercise reduces inflammatory cell production and cardiovascular inflammation via instruction of hematopoietic progenitor cells. Nat Med. 25:1761–1771. 2019.PubMed/NCBI View Article : Google Scholar
17	Zhang Y, Zhang C and Zhang M: A new era of anti-inflammatory therapy for atherosclerosis. Zhonghua Xin Xue Guan Bing Za Zhi. 46:332–337. 2018.PubMed/NCBI View Article : Google Scholar : (In Chinese).
18	Sun YF and Guo DL: Research progress of the relationship between inflammatory factor and coronary heart disease. China Mod Med. 24:12–15. 2017.
19	Szekely Y and Arbel Y: A review of interleukin-1 in heart disease: Where do we stand today? Cardiol Ther. 7:25–44. 2018.PubMed/NCBI View Article : Google Scholar
20	Gao S, Shu S, Wang L, Zhou J and Yuan Z: Pro-inflammatory and anti-inflammatory cytokine responses of peripheral blood mononuclear cells in apparently healthy subjects. Nan Fang Yi Ke Da Xue Xue Bao. 34:1589–1593. 2014.PubMed/NCBI(In Chinese).
21	Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, et al: Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 377:1119–1131. 2017.PubMed/NCBI View Article : Google Scholar
22	Dongxu H, Yundi J, Jia S, Zongyu W, Jiake W, Weili D, Na S, Tongtong Y, Zhijun S and Zaoqing S: The effects of C-reactive protein and albumin ratio on the prognoses in patients with acute coronary syndrome. Chin J Cardiovasc Res. 16:1090–1094. 2018.
23	Hou J, Xia Y, Jiang R, Chen D, Xu J, Deng L, Huang X, Wang X and Sun B: PTPRO plays a dual role in hepatic ischemia reperfusion injury through feedback activation of NF-κB. J Hepatol. 60:306–312. 2014.PubMed/NCBI View Article : Google Scholar